Leukemic cell lines and patients cells to test efficiency of immunotoxins
2017
Indian Institute of Technology Madras, Chennai, India
The study describes a modern therapeutic approach to target chemotherapy-resistant leukemic stem cells (LSCs) to prevent disease relapse. In the present study, the researchers reported for the first time a novel immunotoxin conjugate peptide to specifically target leukemic stem cells. The immunotoxin was tested in a total cell population and LSCs isolated from human leukemic cell lines available from the National Center for Cell Science in Pune, India. Leukemic patients' cells were also used for testing. The developed immunotoxin induced potent cytotoxicity in leukemic cells from cell lines and patient samples. Additionally, the immunotoxin could induce apoptosis also in resistant cell lines, relapsed patient samples and LSCs isolated from leukemic patients and cell lines. Further development of the immunotoxin could prove valuable in a multi-targeted approach to tackle drug resistant leukemia.
CD25 targeted therapy of chemotherapy resistant leukemic stem cells using DR5 specific TRAIL peptide
Rama Shanker Verma
Added on: 07-27-2021
[1] https://www.sciencedirect.com/science/article/pii/S1873506117300016[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
